Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 10:35 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 732 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Systemic Inflammatory Response Syndrome Clear all
Completed Phase 1Phase 2 Interventional Results available

Pharmacokinetic and Biomarker Study of Pioglitazone in Adolescents With Severe Sepsis and Septic Shock

NCT01352182
View directory record Official record
Conditions
Severe Sepsis, Septic Shock
Interventions
Pioglitazone hydrochloride
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Not listed
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 2, 2020 · Synced Oct 21, 2026, 10:35 PM EDT
Completed No phase listed Observational Results available

Inflammatory Cytokine Quantification in Infants

NCT01155830
View directory record Official record
Conditions
Sepsis, Congenital Diaphragmatic Hernia, Neonatal Cardiopulmonary Failure
Interventions
Not listed
Lead sponsor
University of Utah
Other
Eligibility
Up to 2 Months
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
2
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 4, 2015 · Synced Oct 21, 2026, 10:35 PM EDT
Recruiting Not applicable Interventional

Evaluation of Pediatric eCART Implementation

NCT06771830
View directory record Official record
Conditions
Pediatric ALL, Sepsis
Interventions
Pediatric eCART
Device
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
Up to 17 Years
Enrollment
30,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 21, 2026, 10:35 PM EDT
Completed Not applicable Interventional

HeRO Vascular Access Device Bacteremia Study

NCT00889564
View directory record Official record
Conditions
Hemodialysis
Interventions
HeRO Vascular Access Device
Device
Lead sponsor
Merit Medical Systems, Inc.
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
7
States / cities
Miami, Florida • Atlanta, Georgia • Springfield, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2017 · Synced Oct 21, 2026, 10:35 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Detoxified J5 Core Glycolipid/ Group B Meningococcal Outer Membrane Protein Vaccine for Gram-negative Bacterial Sepsis Administered With and Without Synthetic CPG Oligodeoxynucleotide 7909 Adjuvant

NCT01164514
View directory record Official record
Conditions
Bacterial Sepsis
Interventions
CPG 7909, J5-OMP Vaccine, Placebo
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 31, 2014 · Synced Oct 21, 2026, 10:35 PM EDT
Completed No phase listed Observational

Clinical Outcomes and Cost of Gram Negative Bacteremia

NCT02599220
View directory record Official record
Conditions
Gram-negative Bacteremia, Bacteremia
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2015
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 6, 2015 · Synced Oct 21, 2026, 10:35 PM EDT
Completed Phase 3 Interventional

A Prospective, Randomized, Phase III Trial of FLAC (5-Fluorouracil, Leucovorin, Adriamycin, Cytoxan) Chemotherapy With GM-CSF (Granulocyte-Macrophage Colony-Stimulating Factor) Versus PIXY 321 in Advanced Breast Cancer

NCT00001338
View directory record Official record
Conditions
Breast Neoplasms, Fever, Hematologic Diseases, Neutropenia, Sepsis
Interventions
FLAC chemotherapy with GM-CSF
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 21, 2026, 10:35 PM EDT
Terminated No phase listed Observational

Thrombin Generation and Thromboelastography in Non-overt DIC

NCT00299949
View directory record Official record
Conditions
Sepsis, Disseminated Intravascular Coagulation
Interventions
Not listed
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
Not listed
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 8, 2013 · Synced Oct 21, 2026, 10:35 PM EDT
Completed No phase listed Observational

Performance Evaluation of the Nanomix eLab® CRP, PCT, and LAC Assays With the Nanomix eLab System

NCT03876535
View directory record Official record
Conditions
Sepsis, SIRS
Interventions
Nanomix eLab® System molecular diagnostic test (non-interventional)
Other
Lead sponsor
Nanomix
Industry
Eligibility
18 Years and older
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 23, 2021 · Synced Oct 21, 2026, 10:35 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of Intravenous Sulbactam-ETX2514 in the Treatment of Patients With Infections Caused by Acinetobacter Baumannii-calcoaceticus Complex

NCT03894046
View directory record Official record
Conditions
Acinetobacter Baumannii-calcoaceticus Complex, Hospital-acquired Bacterial Pneumonia, Ventilator-associated Bacterial Pneumonia, Bacteremia, Colistin Resistant ABC
Interventions
Sulbactam, Durlobactam, Colistin, Imipenem/Cilastatin 500 mg/500 mg
Drug
Lead sponsor
Entasis Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
5
States / cities
Chicago, Illinois • Shreveport, Louisiana • Cincinnati, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2023 · Synced Oct 21, 2026, 10:35 PM EDT
Completed Phase 4 Interventional Results available

Prophylactic Antimicrobial Catheter Lock

NCT00571259
View directory record Official record
Conditions
Bacteremia
Interventions
Heparin 1000U/mL, 4% Sodium Citrate with Gentamicin 320 mcg/mL
Drug
Lead sponsor
Satellite Healthcare
Other
Eligibility
Not listed
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
Mountain View, California
Source: ClinicalTrials.gov public record
Updated Sep 22, 2021 · Synced Oct 21, 2026, 10:35 PM EDT
Completed Phase 2 Interventional Results available

Randomized Controlled Trial of Calcitriol vs. Placebo Among Critically-ill Patients With Sepsis

NCT01689441
View directory record Official record
Conditions
Severe Sepsis or Septic Shock
Interventions
Calcitriol, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 10, 2020 · Synced Oct 21, 2026, 10:35 PM EDT
Withdrawn Not applicable Interventional

LifeFlow Sepsis Study

NCT07191054
View directory record Official record
Conditions
Sepsis
Interventions
LifeFlow Rapid infuser, Push Pull
Device
Lead sponsor
Phoenix Children's Hospital
Other
Eligibility
1 Year to 19 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 24, 2025 · Synced Oct 21, 2026, 10:35 PM EDT
Terminated Phase 4 Interventional

Procalcitonin Level to Discontinue Antibiotics on ICU Patients With no Obvious Site of Infection

NCT00407147
View directory record Official record
Conditions
Infection, Bacterial Infection, Sepsis
Interventions
Procalcitonin assay - B.R.A.H.M.S PCT sensitive Kryptor
Device
Lead sponsor
Brahms AG
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
3
States / cities
St Louis, Missouri • Camden, New Jersey • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jan 18, 2012 · Synced Oct 21, 2026, 10:35 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Assessing Immune Dysfunction in Sepsis

NCT07154615
View directory record Official record
Conditions
Sepsis
Interventions
Observational Only
Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 21, 2026, 10:35 PM EDT
Completed Phase 3 Interventional Results available

Isavuconazole (BAL8557) in the Treatment of Candidemia and Other Invasive Candida Infections

NCT00413218
View directory record Official record
Conditions
Candidiasis, Invasive, Candidemia, Mycoses
Interventions
Isavuconazole, Caspofungin, Voriconazole
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
18
States / cities
Birmingham, Alabama • Palm Desert, California • Sacramento, California + 15 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2024 · Synced Oct 21, 2026, 10:35 PM EDT
Completed Phase 2 Interventional Results available

Therapeutic Plasma Exchange Alone or in Combination With Ruxolitinib in COVID-19 Associated CRS

NCT04374149
View directory record Official record
Conditions
Cytokine Release Syndrome, COVID19
Interventions
Therapeutic Plasma Exchange, Ruxolitinib
Procedure · Drug
Lead sponsor
Prisma Health-Upstate
Other
Eligibility
12 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Greenville, South Carolina
Source: ClinicalTrials.gov public record
Updated Dec 2, 2021 · Synced Oct 21, 2026, 10:35 PM EDT
Completed No phase listed Observational

Near Infrared Spectroscopy (St02)

NCT01062685
View directory record Official record
Conditions
Septic Shock
Interventions
Near-infrared spectroscopy assessment
Diagnostic Test
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 29, 2024 · Synced Oct 21, 2026, 10:35 PM EDT
Completed Not applicable Interventional Results available

Protocolized Care for Early Septic Shock

NCT00510835
View directory record Official record
Conditions
Sepsis, Severe Sepsis, Septic Shock
Interventions
Early Goal Directed Therapy (EGDT), Protocolized Standard Care (PSC), Usual Care (UC)
Procedure
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
1,351 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
31
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 23 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2017 · Synced Oct 21, 2026, 10:35 PM EDT
Terminated Phase 4 Interventional Results available

Use of Amiodarone in Atrial Fibrillation Associated With Severe Sepsis or Septic Shock

NCT02668432
View directory record Official record
Conditions
New Onset Atrial Fibrillation, Severe Sepsis, Septic Shock
Interventions
Amiodarone
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 2, 2019 · Synced Oct 21, 2026, 10:35 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Micro and Macro Circulation in Sepsis

NCT05694455
View directory record Official record
Conditions
Sepsis, Septic Shock
Interventions
Starling Stroke Volume (Starling SV)- Passive Leg Raise, Microscan Sublingual Microscopy, Venous Excess Ultrasound Scoring (VExUS), Urine Collection
Diagnostic Test · Other
Lead sponsor
Denver Health and Hospital Authority
Other
Eligibility
18 Years to 99 Years
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 5, 2025 · Synced Oct 21, 2026, 10:35 PM EDT
Completed No phase listed Observational

Biomarker Analysis of Stress

NCT00527384
View directory record Official record
Conditions
Sepsis
Interventions
Not listed
Lead sponsor
National Institute of Environmental Health Sciences (NIEHS)
NIH
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Albany, New York
Source: ClinicalTrials.gov public record
Updated Apr 14, 2015 · Synced Oct 21, 2026, 10:35 PM EDT
Completed Phase 4 Interventional Results available

Anidulafungin Versus Fluconazole for the Prevention of Fungal Infections in Liver Transplant Recipients

NCT00841971
View directory record Official record
Conditions
Mycoses, Fungemia, Central Nervous System Fungal Infections, Lung Diseases, Fungal
Interventions
Anidulafungin, Fluconazole
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
6
States / cities
Los Angeles, California • Miami, Florida • Ann Arbor, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2014 · Synced Oct 21, 2026, 10:35 PM EDT
Completed Phase 4 Interventional Results available

Serum Biomarkers to Predict Response to Angiotensin II in Septic Shock

NCT05824767
View directory record Official record
Conditions
Septic Shock, Vasodilatory Shock
Interventions
Angiotensin II
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 21, 2026, 10:35 PM EDT